Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Age ≥ 18 years
Advanced histologically or cytologically confirmed NSCLC (Stage IIIb with malignant pleural or pericardial effusion, Stage IV, or recurrent)
Measurable or non-measurable disease
Prior treatment for CNS disease as deemed appropriate by the treating physician
ECOG performance status 0 or 1
Ability and willingness to comply with study and follow-up procedures
You may not be if
Prior systemic chemotherapy for metastatic disease
Active malignancy other than lung cancer
Current, recent, or planned participation in another experimental drug study
Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib
Adjuvant chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1
Life expectancy of \< 12 weeks
Current, recent, or planned participation in an experimental drug study
Inability to take oral medication or requirement of IV alimentation or total parenteral nutrition, or prior surgical procedures affecting absorption
Inadequate organ function
Known evidence of disseminated intravascular coagulopathy
Active infection or fever \> 38.5°C within 3 days prior to Day 1 of Cycle 1
Untreated abnormal thyroid function tests as defined by institutional standards (patients with controlled hypothyroidism are eligible for study participation)
Any other medical condition(s) (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results
Intrathoracic lung carcinoma of squamous cell histology
Known CNS disease except for treated brain metastases
Inadequately controlled hypertension
Prior history of hypertensive crisis or hypertensive encephalopathy
New York Heart Association (NYHA) Class II or greater CHF
History of myocardial infarction or unstable angina within 12 months prior to Day 1 of Cycle 1
History of stroke or transient ischemic attack within 12 months prior to Day 1 of Cycle 1
Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1
History of hemoptysis within 1 month prior to Day 1 of Cycle 1
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during the course of the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of Cycle 1
History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of Cycle 1
Serious, non-healing wound, active ulcer, or untreated bone fracture
Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
Known hypersensitivity to any component of bevacizumab or sunitinib
Pregnancy (positive pregnancy test) or lactation
Clareo Health | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
